# Enanta Pharmaceuticals Inc. (ENTA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.08, market value $410 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Enanta Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.3×**. Each dollar of revenue is priced at 6.3×.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.0%** (5-yr avg -23.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -90.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -125.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -126.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -22.5%**. Each dollar of assets produces -22.5% of profit.

## Growth
- **Revenue growth (1 yr): -3.4%** (3-yr -8.8%/yr, 5-yr -11.8%/yr). Revenue fell 3.4% over the last year, against -11.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 29.9%**. Earnings per share rose 29.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 4.21** (quick 4.21). Current assets cover the next year's liabilities 4.21 times.
- **Altman Z-score: 1.36**. A Z-score of 1.36 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Enanta Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Enanta Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $19.80 (+41% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 58.4%** (YTD -10.7%, 3-mo 24.8%). The shares are up 58.4% over twelve months including dividends.
- **From 52-week high: -17.9%** (99.7% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 0.98** (volatility 108%). Beta of 0.98 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ENTA · Page: https://foliofundamentals.com/stocks/enta

Not investment advice.